Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Detoxified O-Specific Polysaccharide (O-SP)–Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene
Dani Cohen, Shiri Meron-Sudai, Anya Bialik, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 675-675
Open Access | Times Cited: 11

Showing 11 citing articles:

The Shigella Vaccines Pipeline
Calman A. MacLennan, Stephanie Grow, Lyou‐Fu Ma, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1376-1376
Open Access | Times Cited: 73
Recent updates on correlates of vaccine-induced protection
Stanley A. Plotkin
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 47
Toward a Shigella Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen
Maria Michelina Raso, Vanessa Arato, Gianmarco Gasperini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4649-4649
Open Access | Times Cited: 22
Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent Vaccine against Shigella
Francesca Mancini, Renzo Alfini, Valentina Caradonna, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2742-2742
Open Access | Times Cited: 13
A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
Shiri Meron-Sudai, Valeria Asato, Amos Adler, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 9
Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry
Meagan Kelly, Anjali Mandlik, Richelle C. Charles, et al.
Vaccine (2023) Vol. 41, Iss. 34, pp. 4967-4977
Open Access | Times Cited: 7
Frontiers in Shigella Vaccine Development
Calman A. MacLennan, A. Duncan Steele
Vaccines (2022) Vol. 10, Iss. 9, pp. 1536-1536
Open Access | Times Cited: 12
Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (Invaplex AR ) vaccines
K. Ross Turbyfill, Kristen A. Clarkson, Edwin V. Oaks, et al.
mSphere (2023) Vol. 8, Iss. 4
Open Access | Times Cited: 5
Hit ‘em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target
Alan S. Cross
Microbiology and Molecular Biology Reviews (2023) Vol. 87, Iss. 3
Open Access | Times Cited: 5
Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge
Meagan Kelly, Jeshina Janardhanan, Chanchal Wagh, et al.
Vaccine (2024) Vol. 42, Iss. 24, pp. 126263-126263
Open Access | Times Cited: 1
Comparison of Shigella GMMA and glycoconjugate four-component formulations in animals
Roberta Di Benedetto, Francesca Mancini, Valentina Caradonna, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 1
Page 1

Scroll to top